DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2014; 139(41): 2082-2085DOI: 10.1055/s-0034-1387290 Aktuelle Diagnostik & Therapie | Review article Onkologie, Urologie © Georg Thieme Verlag KG Stuttgart · New YorkHochmaligne B-Zell-Lymphome: moderne Diagnostik und TherapieAggressive B-cell lymphoma: modern diagnostics and treatment N. Schmitz 1 Abt. Hämatologie, Onkologie und Stammzelltransplantation, Asklepios Klinik St. Georg, Hamburg , H. S. Wu 1 Abt. Hämatologie, Onkologie und Stammzelltransplantation, Asklepios Klinik St. Georg, Hamburg , B. Glaß 1 Abt. Hämatologie, Onkologie und Stammzelltransplantation, Asklepios Klinik St. Georg, Hamburg› Author AffiliationsRecommend Article Abstract Buy ArticleSchlüsselwörter Schlüsselwörteraggressives B-Zell-Lymphom - Diagnostik - Therapie Keywords Keywordsaggressive B-cell lymphoma - diagnosis - treatment Full Text References Literatur 1 Coiffier B, Thieblemont C, van den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-2045 2 Cunningham D, Hawkes EA, Jack A et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. Lancet 2013; 381: 1817-1826 3 Gisselbrecht C, Glass B, Mounier N et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190 4 Glass B, Hasenkamp J, Wulf G et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3). Lancet Oncol 2014; 15: 757-766 5 Held G, Zeynalova S, Murawski N et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol 2013; 31: 4115-4122 6 Korfel A, Elter T, Thiel E et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013; 98: 364-370 7 Mounier N, El Gnaoui T, Tilly H et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. Haematologica 2013; 98: 1726-1731 8 Pettengell R, Coiffier B, Narayanan G et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphomal. Lancet Oncol 2012; 13: 696-606 9 Peyrade F, Jardin F, Thieblemont C et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma. Lancet Oncol 2011; 12: 460-468 10 Pfreundschuh M, Ho AD, Cavallin-Stahl E et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 2008; 9: 435-444 11 Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116 12 Récher C, Coiffier B, Haioun C et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B). Lancet 2011; 378: 1858-1867 13 Schmitz N, Nickelsen M, Ziepert M et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012; 13: 1250-1259 14 Schmitz N, Ziepert M, Vitolo U German High-Grade Non-Hodgkin’s Lymphoma Study Group. Fondazione Italiana Linfomi. The role of myeloablation for lymphoma. N Engl J Med 2014; 370: 574-575 15 Schmitz N, Wu HS, Zeynalova S. Risk of CNS recurrence and role of prophylaxis in aggressive lymphoid malignancies. Blood 2014; in press. 16 Stiff PJ, Unger JM, Cook JR et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013; 369: 1681-1690 17 The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994 18 Vitolo U, Chiappella A, Ferreri AJ et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 2011; 29: 2766-2772 19 Wilson WH, Jung SH, Porcu P et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012; 97: 758-765 20 Ziepert M, Hasenclever D, Kuhnt E et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373-2380
